ABSTRACT
The clinical observation of a possible relation between the phases of the menstrual cycle and psychotic illness dates well back to the beginning of the nineteenth century. This relation is considered to provide further evidence for the protective effect of oestrogens in schizophrenic women and is summarised by the so-called oestrogen hypothesis. In addition, the hypoestrogenism hypothesis postulates a hypofunction of the gonads in women with schizophrenia with subsequent oestrogen deficiency syndrome. The aim of the present clinical study was to answer the question whether there is a perimenstrual increase in hospital admissions of women suffering from an exacerbation of schizophrenia. Two samples of premenopausal women with schizophrenia were investigated (sample 1: n = 115; sample 2: n = 170). In both samples there was a significant increase in admissions in the perimenstrual phase - three days before and three days after the first day of the menses (sample 1: P = 0.002, sample 2: P = 0.028, binomial test). 37.4% of the patients were admitted during the perimenstrual phase of the cycle in sample 1, 31.8% in sample 2. Regarding age, age at onset, and duration of illness, no difference was found between the group admitted to hospital during the perimenstrual phase versus the group admitted during the rest of the menstrual cycle in either of the samples. The results are discussed in relation to the possibly underlying physiological mechanisms.
Subject(s)
Menstrual Cycle , Schizophrenia/epidemiology , Adult , Analysis of Variance , Estrogens/blood , Female , Germany/epidemiology , Hospitalization/statistics & numerical data , HumansABSTRACT
OBJECTIVE: To determine whether alterations in the secretion and regulation of matrix metalloproteinases (MMPs) and their inhibitors are present in uterine endometrial cells from endometriosis patients. STUDY DESIGN: In an in vitro study, uterine endometrial cells from 19 regularly cycling women with and 32 without endometriosis were treated with diethyl stilbestrol, promegestone (R5020), interleukin-1 (IL-1) and tumor necrosis factor a (TNF-alpha). Culture supernatants were assayed for MMPs 1, 2, 3, and 9, and for tissue inhibitors of MMP (TIMP-1 and TIMP-2) by ELISA. RESULTS: MMP-3 was secreted in high concentrations, moderate concentrations were seen for MMP-1 and MMP-2, and very low concentrations for MMP-9. Substantially more TIMP-1 than TIMP-2 was secreted. MMP-1 and MMP-3 were uniformly attenuated by R5020, while MMP-2 was not influenced by hormone treatment. MMP-3 was upregulated by TNF-alpha in all samples while IL-1 only increased secretion in cells from endometriosis patients. CONCLUSION: The upregulation of MMP-3 by IL-1 may contribute to an increased invasiveness of uterine endometrial fragments in endometriosis patients.
Subject(s)
Endometriosis/enzymology , Endometrium/enzymology , Matrix Metalloproteinases/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Adult , Cells, Cultured , Diethylstilbestrol/pharmacology , Female , Humans , Interleukin-1/pharmacology , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 9/metabolism , Promegestone/pharmacology , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Musk xylene (MX), musk ketone (MK), musk ambrette, musk moskene, and musk tibetene are synthetic fragrances. Between 1994 and 1996 these five nitromusk compounds (NMCs) were tested in the blood of 152 women who consulted the Endocrinological Department of the University Hospital of Obstetrics and Gynecology, Heidelberg, Germany, because of gynecological problems. The testing was conducted by gas chromotography with mass-specific detector and mass spectrometry in a retrospective cross-sectional study. MX was detected in 95% and MK in 85% of the blood samples (>20 ng per liter whole blood). The median concentration of MX was 65.5 ng/L and the maximum level of MX was 1183 ng/L; the corresponding values for MK were respectively 55.5 and 518 ng/L. The other three NMCs were found in only a few patients or not at all. Significant associations between MX and MK concentrations were found in blood and different clinical parameters of the endocrine system. MX and MK may act centrally as a disrupter of the (supra-) hypothalamic-ovarian axis, which may result in a mild ovarian insufficiency. On the basis of our data, a reproductive toxicity and an endocrine effect of NMCs in women cannot be ruled out. Further experimental and clinical studies should be conducted.
Subject(s)
Endocrine System Diseases/chemically induced , Genital Diseases, Female/chemically induced , Luteinizing Hormone/blood , Perfume/analysis , Xylenes/blood , Adult , Cross-Sectional Studies , Dinitrobenzenes/blood , Dose-Response Relationship, Drug , Endocrine System Diseases/blood , Female , Gas Chromatography-Mass Spectrometry/methods , Genital Diseases, Female/blood , Hirsutism/blood , Hirsutism/chemically induced , Humans , Indans/blood , Luteinizing Hormone/drug effects , Mutagens , Perfume/adverse effects , Premenstrual Syndrome/blood , Premenstrual Syndrome/chemically induced , Retrospective Studies , Skin Absorption , Xylenes/adverse effectsABSTRACT
OBJECTIVE AND DESIGN: In a prospective, randomized, placebo-controlled, double-blind study, the effects of Phyto Hypophyson L (Steierl-Pharma GmbH, Herrsching, Germany), an Agnus castus-containing homeopathic preparation, were investigated in 67 women with fertility disorders. PATIENTS AND METHODS: 37 women with oligomenorrhea and 30 women with amenorrhea received 50 drops of Phyto Hypophyson L or placebo 3 times a day over 3 months or 3 cycles. OUTCOME MEASURE AND RESULTS: The outcome measure being spontaneous menstruation, improved concentration of progesterone in the luteal phase, shortening of the cycle, earlier ovulation, and pregnancy was achieved in 38 out of 67 women. It was achieved more often from women with oligomenorrhea in the Phyto Hypophyson L group compared to the placebo group (82 versus 45%, p = 0.021). However, there was no significant effect when viewing the whole group. The baby take-home rate during the therapy and 6 months after the end of the therapy showed a ratio of 6 : 2 (18.7 : 6.4%). This result was not significant. Furthermore, in the oligomenorrhea verum group we observed a significant increase of progesterone during the luteal phase compared to the oligomenorrhea placebo group. Only very few undesirable drug effects were observed. CONCLUSION: In women with sterility and oligomenorrhea, a treatment with Phyto Hypophyson L can be recommended over a period of 3-6 months.
Subject(s)
Homeopathy , Infertility, Female/drug therapy , Phytotherapy , Plants, Medicinal , Vitex/therapeutic use , Adult , Amenorrhea/drug therapy , Double-Blind Method , Female , Humans , Infant, Newborn , Oligomenorrhea/drug therapy , Placebos , Pregnancy , Pregnancy Outcome , Prospective StudiesABSTRACT
Local invasiveness is an important prognostic factor in endometrial carcinoma. To study the role of two groups of secreted proteinases (serine proteinases and matrix metalloproteinases) in this process, we examined three endometrial cancer cell lines (Ishikawa HEC 1A, AN3CA) for their invasiveness in vitro. Additionally, we considered the secretion of urokinase type plasminogen activator (uPA), plasminogen activator inhibitor 1 and 2 (PAI-1 and PAI-2), as well as matrix metalloproteinases (MMP) 1, 2, 3, and 9, and their inhibitors TIMP-1 and TIMP-2. Compared to the highly invasive fibrosarcoma cell line HT 1080, Ishikawa displayed low and AN3CA moderate invasiveness, while HEC 1A cells were almost as invasive as HT 1080 cells. Ishikawa cells secreted the highest amounts of proteinases. Cytokine and steroid treatments upregulated MMP-1 in all cell lines while the effects were heterogeneous regarding other proteinases and inhibitors. No effect of these treatments on invasiveness could be detected. Both basal secretion and regulation of the proteinases tested in this set of experiments seem to be markers of differentiation rather than of invasiveness.
Subject(s)
Endometrial Neoplasms/metabolism , Endometrial Neoplasms/pathology , Matrix Metalloproteinases/metabolism , Serine Endopeptidases/metabolism , Cell Differentiation , Female , Humans , Neoplasm Invasiveness , Plasminogen Activator Inhibitor 1/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism , Tumor Cells, Cultured , Urokinase-Type Plasminogen Activator/metabolismABSTRACT
OBJECTIVES: (1) to demonstrate specificity of integrin function in endometrial cell adhesion; (2) to investigate their regulation by tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1); and (3) to detect differences between cells from patients with and without endometriosis. STUDY DESIGN: Endometrial cell cultures from ten patients with and 13 without endometriosis were tested for their expression of integrins alpha2beta1, alpha5beta1, alpha(v)beta3, and alpha4beta1 by immunocytochemistry and for their adhesion to collagen type IV, laminin, and fibronectin. RESULTS: Integrin expression was independent of cytokine treatment. Addition of antiintegrin antibodies inhibited adhesion. A significant increase in adhesion to laminin and fibronectin was seen in endometriosis after IL-1 treatment and additionally to collagen after TNF alpha. Cells from women without endometriosis showed a significant increase only to fibronectin. CONCLUSIONS: Human endometrial cells express functional integrins in vitro. TNF alpha and IL-1 had more pronounced effects on adhesion in endometriosis. Inflammatory cytokines in the peritoneal cavity may facilitate adhesion of retrogradely menstruated endometrial fragments in endometriosis.
Subject(s)
Endometriosis/pathology , Endometrium/pathology , Extracellular Matrix Proteins/physiology , Integrins/physiology , Interleukin-1/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Adult , Cell Death/drug effects , Endometriosis/etiology , Female , HumansABSTRACT
To investigate the effect of medrogestone on bone mineral density (BMD) and bone turnover under conditions of estrogen withdrawal, premenopausal women with endometriosis were treated with goserelin (Zoladex), combined with either placebo (group A, n = 12) or 10 mg medrogestone (Prothil, group B, n = 11) for six months, and followed for an additional six months. Lumbar spine BMD was measured at 0 and 6 month. Markers of bone turnover were serum bone alkaline phosphatase (sBAP) and osteocalcin (sOC) by ELISA, and urinary total pyridinoline (uPYD) and deoxypyridinoline crosslinks (uDPD) by HPLC. Patients in both groups had a similar and significant decrease in BMD after 6 months (4%, p < 0.01). The time course of changes in bone turnover, in contrast, was different in both groups. In group A, crosslink excretion increased from one month onwards, while no changes were seen in group B. In group A, sBAP levels rose during treatment, while in group B, this rise was delayed until treatment was terminated. Additionally, group B showed an initial suppression of sBAP and sOC. In both groups, sOC increased after treatment was discontinued. Medrogestone at 10 mg/d does not prevent lumbar bone loss in premenopausal women under estrogen deprivation. In the medrogestone add back group, the changes in bone turnover are compatible with low turnover bone loss,as ooposed to a state of high turnover seen in the unopposed goserelin group. This effect may be due to glucocorticoid receptor mediated actions of medrogestone on bone.
Subject(s)
Bone Remodeling , Endometriosis/drug therapy , Goserelin/therapeutic use , Medrogestone/therapeutic use , Premenopause , Progesterone Congeners/therapeutic use , Adult , Alkaline Phosphatase/blood , Amino Acids/urine , Bone Density , Bone and Bones/enzymology , Double-Blind Method , Endometriosis/physiopathology , Female , Humans , Kinetics , Osteocalcin/blood , Osteoporosis/prevention & control , PlacebosSubject(s)
Estrogen Replacement Therapy , Progestins/therapeutic use , Adult , Climacteric , Estrogen Replacement Therapy/adverse effects , Female , Humans , Mammography , Middle Aged , Myocardial Infarction/prevention & control , Postmenopause , Progestins/adverse effects , Risk Factors , Uterine Neoplasms/prevention & controlABSTRACT
This study was conducted to investigate the hypothesis that chlorinated hydrocarbons (CHC) may affect fertility in women. In 489 infertile women, CHC levels were measured in whole blood. Different anamnestic and clinical parameters were obtained or investigated in order to detect possible associations to CHC concentrations. CHC levels were correlated to the women's age, body mass index, and nationality. Especially in women with uterine fibroids, endometriosis, miscarriages, persistent infertility, and hormonal disturbances, elevated concentrations of chlorinated hydrocarbons with long half-lives were observed. Chlorinated hydrocarbons may play a role in female infertility and may be an underlying factor in certain gynecological conditions.
Subject(s)
Hydrocarbons, Chlorinated/blood , Infertility, Female/blood , Abortion, Spontaneous/blood , Abortion, Spontaneous/etiology , Adult , Age Factors , Body Mass Index , Endocrine System Diseases/blood , Endometriosis/blood , Endometriosis/etiology , Environmental Exposure , Female , Germany , Half-Life , Humans , Hydrocarbons, Chlorinated/adverse effects , Hyperandrogenism/blood , Hyperandrogenism/etiology , Hyperprolactinemia/blood , Hyperprolactinemia/etiology , Leiomyoma/blood , Pregnancy , Seasons , Turkey/ethnologyABSTRACT
Exposure to wood preservatives containing pentachlorophenol (PCP) was detected in 65 women who consulted the Endocrinological Department of the University Hospital of Obstetrics and Gynecology, Heidelberg, Germany, because of gynecological problems. Blood PCP levels ranged from 20.7 to 133 microg per liter of serum. One hundred and six women with similar clinical conditions, corresponding age and body weight, no PCP exposure in history, and PCP levels below 20 microg per liter of serum served as control group. Significant associations were found between serum PCP concentrations, age, and different parameters of the endocrine system. PCP may act centrally on a hypothalamic or suprahypothalamic level which may result in mild ovarian and adrenal insufficiency. PCP may, therefore, play a role in the increasing infertility problem.
Subject(s)
Endocrine System Diseases/blood , Environmental Exposure , Genital Diseases, Female/blood , Pentachlorophenol/adverse effects , Adrenal Cortex Hormones/blood , Adrenal Glands/drug effects , Adrenal Glands/metabolism , Age Factors , Endocrine System Diseases/chemically induced , Female , Genital Diseases, Female/chemically induced , Germany , Gonadal Steroid Hormones/blood , Humans , Infertility, Female/blood , Infertility, Female/chemically induced , Matched-Pair Analysis , Ovary/drug effects , Ovary/metabolism , Pentachlorophenol/blood , Pregnancy , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Thyroid Hormones/bloodABSTRACT
Proliferation of granulosa cells is inversely related to differentiation and hormone production. The purpose of this study was to evaluate the intrafollicular and serum steroid concentrations and to compare these results to granulosa cell proliferation as measured by DNA flow cytometry. Human granulosa lutein cells in follicular fluid of in-vitro fertilization (IVF) patients were investigated with regard to ploidy, percentage of S-phase cells and proliferation index (PI: percentage of cells in the S- and G2/M-phase). The study was originally designed to indicate an additional marker for the outcome of IVF treatment by DNA flow cytometric measurements of granulosa lutein cells. Follicular fluids of 160 follicles (45 patients) were evaluated; 45.6% (n = 73) of the follicles showed aneuploid granulosa lutein cells and 5.6% (n = 9) of the follicles contained multiploid granulosa cells, defined as at least two aneuploid populations of cells with different DNA indices. A total of 48.8% (n = 78) of the follicles had only diploid cells. Thus >50 % of the investigated follicles showed aneuploidy. In all, 73% (33 of 45) of patients had at least one follicle containing aneuploid granulosa lutein cells. The PI of the aneuploid cell populations significantly exceeded that of the diploid cell populations (median: aneuploid: 15.5; diploid: 7.4; P < 0.0001). The intrafollicular concentrations of testosterone, progesterone and dehydroepiandrosterone sulphate (DHEA-S) were significantly lower in follicles with aneuploid granulosa cell populations. Luteinizing hormone concentration was significantly higher in follicles with aneuploid granulosa cells. Intrafollicular concentrations of oestradiol, follicle stimulating hormone and the serum concentrations of all steroid hormones did not show any significant correlation to ploidy. Although aneuploidy has been reported for oocytes (in approximately 17% of the oocytes), no study, to our knowledge, has observed such a high incidence of aneuploidy in granulosa lutein cells after gonadotrophin stimulation. Except for aneuploidy found in tissues with some characteristics of neoplastic growth (colon adenoma, borderline tumours, endometriosis with atypic cells, etc.), it is unique for non-malignant human cells. The correlation with intrafollicular steroid concentrations points to a possible pathophysiological or physiological relevance of these findings. However, it was impossible to correlate the outcome of IVF with DNA flow cytometry results.
Subject(s)
Aneuploidy , Follicular Fluid/metabolism , Hormones/metabolism , Luteal Cells/metabolism , Ovarian Follicle/cytology , Adult , Age Factors , Apoptosis , Cell Division , Chorionic Gonadotropin/pharmacology , DNA/genetics , DNA/metabolism , Female , Fertilization in Vitro , Flow Cytometry , Humans , Middle Aged , Ovarian Follicle/drug effects , Ovarian Follicle/metabolism , Ovarian Neoplasms/etiology , Ovulation Induction/adverse effects , S PhaseABSTRACT
This study was conducted to investigate a possible etiological role of chlorinated hydrocarbons in the pathogenesis of repeated miscarriages. The blood levels of chlorinated hydrocarbons [CHCs: pentachlorophenol, hexachlorocyclohexane, hexachlorobenzene, the dichlorodiphenyltrichloroethane (DDT) group, polychlorinated biphenyls] were determined in 89 women with repeated miscarriages, who were referred to the University Hospital of Obstetrics and Gynecology of Heidelberg for investigations between 1989 and 1993, and compared to a previously investigated reference population. In more than 20% of the women, at least one of the CHC levels exceeded the reference range. CHC levels did not differ significantly between women with primary or secondary and early or late miscarriages; neither did they differ between women with hormonal or immunological disorders as causes of repeated miscarriages or women with idiopathic repeated miscarriages. No significant associations were detected between CHC levels and further conceptions or the outcome of further pregnancies. As significant associations were found between increasing CHC blood concentrations and immunological and hormonal changes, CHCs may have an impact on the pregnancy course in certain cases.
Subject(s)
Abortion, Habitual/blood , Hydrocarbons, Chlorinated/blood , Abortion, Habitual/epidemiology , Abortion, Habitual/etiology , Adult , Female , Germany/epidemiology , Hexachlorocyclohexane/blood , Humans , Pentachlorophenol/blood , PregnancyABSTRACT
Heavy metals have been identified as factors affecting human fertility. This study was designed to investigate whether the urinary heavy metal excretion is associated with different factors of infertility. The urinary heavy metal excretion was determined in 501 infertile women after oral administration of the chelating agent 2,3-dimercaptopropane-1-sulfonic acid (DMPS). Furthermore, the influence of trace element and vitamin administration on metal excretion was investigated. Significant correlations were found between different heavy metals and clinical parameters (age, body mass index, nationality) as well as gynecological conditions (uterine fibroids, miscarriages, hormonal disorders). Diagnosis and reduction of an increased heavy metal body load improved the spontaneous conception chances of infertile women. The DMPS test was a useful and complementary diagnostic method. Adequate treatment provides successful alternatives to conventional hormonal therapy.
Subject(s)
Hormones/blood , Infertility, Female/blood , Infertility, Female/urine , Metals, Heavy/urine , Adult , Age Factors , Body Burden , Cadmium/urine , Chelating Agents , Dental Amalgam , Endocrine System Diseases/blood , Endocrine System Diseases/urine , Female , Germany , Humans , Infertility, Female/diagnosis , Mercury/urine , UnithiolABSTRACT
In 111 women with repeated miscarriages, the urinary excretion of heavy metals was determined in a challenge test with the chelating agent 2,3-dimercaptopropane-1-sulphonic acid in addition to hormonal, chromosomal, immunological and uterine investigations. The heavy metal excretion was correlated to different immunological (natural killer cells, T cell subpopulations) and hormonal (progesterone, oestradiol, prolactin, thyroid stimulating hormone) parameters. We conclude that heavy metals seem to have a negative impact on ovarian as well as on pituitary function. The heavy metal-induced immunological changes may interfere with the physiological adaptation of the immune system to the state of pregnancy with the result of a miscarriage. The observed heavy metal-induced hormonal and immunological changes may be important factors in the pathogenesis of repeated miscarriages.
Subject(s)
Abortion, Habitual , Hormones , Immunity , Metals, Heavy , Abortion, Habitual/blood , Abortion, Habitual/immunology , Abortion, Habitual/urine , Chelating Agents , Female , Humans , Lymphocytes/immunology , Metals, Heavy/urine , PregnancyABSTRACT
The aim of this study was to investigate the direct effect of 5-lipoxygenase (5-LO) on the growth of human mammary cancer cells MCF-7 in vitro. Cell growth was measured according to the level of 3H-thymidine incorporation. 5-LO was shown to inhibit 3H-thymidine incorporation. The inhibitory effect was 19, 42 and 78% when administered at concentrations of 0.1, 0.2 or 0.5 U/ml, respectively. Its effect was time- and dose-dependent and was statistically significant at concentrations of 0.2 and 0.5 U/ml. We have also shown that the specific 5-LO inhibitor MK-886 (1 microM) lifts the inhibitory effect of 5-LO (0.2 U/ml). Moreover, when treated with an activator of 5-lipoxygenase calcium ionophore A23187 (10 microM) MCF-7 cells synthesize LTB4. The results of this study are evidence of the role of 5-lipoxygenase in the regulation of human mammary cancer cells growth in vitro.
Subject(s)
Arachidonate 5-Lipoxygenase/pharmacology , Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Breast Neoplasms/metabolism , Calcimycin/pharmacology , Cell Division/drug effects , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Humans , Indoles/pharmacology , Leukotriene B4/biosynthesis , Lipoxygenase Inhibitors/pharmacology , Thymidine/metabolism , Tumor Cells, CulturedABSTRACT
In asymptomatic infertility patients, no significant relationship was found between the presence of antisperm antibodies (ASA) in serum and in semen samples (IgG and/or IgA ASA), differentiated with the mixed antiglobulin reaction (MAR), and the microbial colonization of ejaculates covering a broad spectrum of microorganisms. Likewise, there was no significant association of ASA with microbial findings in patients' female partners, who also presented without symptoms of genital tract infection and were screened at the same time. Furthermore, ASA in semen (IgG and IgA) were not significantly related to several potential markers of subclinical male sexual gland infection or inflammation (leukocytes, PMN elastase, albumin, C3c) evaluated in aliquots of the same ejaculates used for immunological testing.